
    
      This is an open-label safety and pharmacokinetic (PK) study involving a single application of
      Ha44 Gel 0.74% administered under maximal use conditions.

      All participants must have an active head lice infestation (at least 3 live lice) and be 6
      months to 17 years of age. The study will enroll approximately 36 pediatric subjects between
      the ages of 6 months and 17 years.

      Pediatric PK samples will be collected at 0 (predose), 30 and 60 mins and 2 and 8 hrs time
      points.

      More than one household member with an active lice infestation may participate in the study.
      Eligible subjects will be consented and screened for study eligibility on Day 0 (Visit 1).
      All subjects will return to the study site for three follow-up clinic visits at Days 1, 7 and
      14. The maximum study duration for a subject is 16 days.
    
  